中文

Hong Kong Stocks · Free Data Page

GIANT BIOGENE 02367

GIANT BIOGENE: FY2025 revenue CN¥5.52B (-0.40% YoY); net income CN¥1.91B; 0 alerts, 1 watch item out of 17 risk checks; TTM dividend HK$1.39/sh.
Close PriceHK$20.40Day -0.39%Market CapHK$21.66BP/E11.4xTTMP/B2.01xDividend Yield6.81%TTMROE (FY2025)22.5%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for GIANT BIOGENE?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2019–2025

Financial statements are reported in CNY, while share price and market cap are quoted in HKD.

Key Multi-Year Facts

  • Revenue moved from CN¥956.7M in FY2019 to CN¥5.52B in FY2025 (6-year CAGR +33.9%).
  • Profitable in every fiscal year across 2019–2025.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (CNY B)1.552.363.525.545.52
YoY30.4%52.3%49.0%57.2%-0.4%
Net Income (CNY B)0.831.001.452.061.91
YoY0.2%21.0%44.9%42.1%-7.2%
Operating Cash Flow (CNY B)0.690.931.652.041.78
ROE112.3%52.0%40.4%36.0%22.5%
Gross Margin87.2%84.4%83.6%82.1%80.3%
Net Margin53.3%42.4%41.2%37.2%34.7%
Debt-to-Assets87.1%9.6%12.1%11.4%8.5%
Show all 7 fiscal years
Fiscal Year2019202020212022202320242025
Revenue (CNY B)0.961.191.552.363.525.545.52
YoY—24.4%30.4%52.3%49.0%57.2%-0.4%
Net Income (CNY B)0.550.830.831.001.452.061.91
YoY—49.6%0.2%21.0%44.9%42.1%-7.2%
Operating Cash Flow (CNY B)0.660.830.690.931.652.041.78
ROE48.1%102.9%112.3%52.0%40.4%36.0%22.5%
Gross Margin83.3%84.6%87.2%84.4%83.6%82.1%80.3%
Net Margin57.7%69.4%53.3%42.4%41.2%37.2%34.7%
Debt-to-Assets35.9%82.7%87.1%9.6%12.1%11.4%8.5%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

0Alert 1Watch 15Pass 1N/A

Items Flagged for Review

  • Watch

    Auditor ChangeMaterial Events

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

Trailing 12-month dividend: HK$1.389 per share, or 6.81% yield at closing price; last full fiscal year: HK$1.389 (payout ratio 77.5%).

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.